What the policy lists
| Prior authorization | listed in the policy |
|---|---|
| Quantity limit | listed in the policy |
Cigna's documents for adalimumab
- Drug Quantity Management, Adalimumab Products (policy DQM005)
- Inflammatory Conditions, Adalimumab Products Prior Authorization Policy (policy IP0652)
What your plan's policy says
The plan's document holds the details for this medicine.
What this medicine is used for
“Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.”
“Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis .”
“Reducing signs and symptoms in adult patients with active ankylosing spondylitis .”
“Treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older.”
“Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.”
“Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.”
“Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.”
“Rheumatoid Arthritis HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.”
“Juvenile Idiopathic Arthritis HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.”
“Psoriatic Arthritis HUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.”
“Ankylosing Spondylitis HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.”
“Ulcerative Colitis HUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older.”
“Plaque Psoriasis HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.”
“Hidradenitis Suppurativa HUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.”
From the FDA label for Humira, revised December 23, 2025. The label is shown in English as published. DailyMed. Your doctor decides what it is used for in your case.
Common questions
Does Cigna require prior authorization for adalimumab?
Cigna's published policy lists prior authorization for adalimumab.
Does Cigna have a quantity limit for adalimumab?
Cigna's published policy lists a quantity limit for adalimumab.
How do I see the policy for my own plan and state?
Open the free KAIS guide, pick your plan, your type of plan, your state and your medicine, and it shows the policy your plan publishes, with the link to the plan's own document.
Not medical advice and not a decision on your claim. Your doctor and your plan decide.